EFFECT OF CEFEPIME ON RESPIRATORY TRACT INFECTION

• Published in: CHEMOTHERAPY Vol. 39; no. Supplement2; pp. 425 - 428
• Main Authors: Yamaki, Kenichi, Suzuki, Kenji, Takagi, Kenzo, Satake, Tatsuo, Noda, Yasunobu, Gonda, Hideo, Suzuki, Michio, Suzuki, Kiyoshi, Watanabe, Hisayoshi
• Format: Journal Article
• Language: English; Japanese
• Published: Japanese Society of Chemotherapy 1991
• Subjects: Cefepime
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.39.Supplement2_425

Cefepime, a new cephalosporin producted from Bristol-Myers Laboratory with activity against Gram-positive and Gram-negative bacteria, was administered intravenously at a daily dose of 2 g to 10 patients with respiratory tract infection, including pneumonia (5 cases), chronic bronchitis (4 cases) and bronchiectasis with secondary infection (1 case). The overall clinical efficacy was 80%. The isolated organisms from sputum were eradicated in all 7 cases and bacterial replacement was observed in 2 of 7 cases. The only side effect of slight fever was observed in one patient who also had abnormal laboratory findings (slight elevation of GOT·GPT). These results indicate that cefepime is a valuable antibiotic for respiratory tract infection.